Inga Rose

566 total citations · 1 hit paper
8 papers, 446 citations indexed

About

Inga Rose is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Inga Rose has authored 8 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cancer Research and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Inga Rose's work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer Cells and Metastasis (2 papers). Inga Rose is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer Cells and Metastasis (2 papers). Inga Rose collaborates with scholars based in United States, Qatar and Bosnia and Herzegovina. Inga Rose's co-authors include Zoran Gatalica, Omid Hamid, Anatole Ghazalpour, Semir Vranić, Daniel A. Holterman, Daniel D. Von Hoff, Nianqing Xiao, Gargi D. Basu, Todd Maney and Carrie Snyder and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Epidemiology Biomarkers & Prevention.

In The Last Decade

Inga Rose

8 papers receiving 445 citations

Hit Papers

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in ... 2014 2026 2018 2022 2014 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inga Rose United States 5 367 155 121 83 70 8 446
Todd Maney United States 5 389 1.1× 154 1.0× 130 1.1× 100 1.2× 67 1.0× 9 484
Judith Lindner Germany 7 251 0.7× 103 0.7× 82 0.7× 54 0.7× 22 0.3× 11 341
Joon Young Hur South Korea 10 238 0.6× 139 0.9× 84 0.7× 47 0.6× 49 0.7× 26 346
Xin-Ke Zhang China 7 215 0.6× 78 0.5× 118 1.0× 57 0.7× 24 0.3× 9 359
Andy Karabajakian France 9 537 1.5× 138 0.9× 246 2.0× 84 1.0× 33 0.5× 19 684
JT Chang United States 2 497 1.4× 193 1.2× 281 2.3× 215 2.6× 58 0.8× 5 689
Lauriane Eberst France 10 215 0.6× 82 0.5× 164 1.4× 37 0.4× 24 0.3× 38 415
Ryo Yoriki Japan 5 608 1.7× 341 2.2× 159 1.3× 57 0.7× 51 0.7× 10 717
Yuichiro Ohigashi Japan 2 583 1.6× 329 2.1× 152 1.3× 36 0.4× 45 0.6× 4 662
Rania Chehade Canada 8 327 0.9× 66 0.4× 174 1.4× 58 0.7× 25 0.4× 21 485

Countries citing papers authored by Inga Rose

Since Specialization
Citations

This map shows the geographic impact of Inga Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inga Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inga Rose more than expected).

Fields of papers citing papers by Inga Rose

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inga Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inga Rose. The network helps show where Inga Rose may publish in the future.

Co-authorship network of co-authors of Inga Rose

This figure shows the co-authorship network connecting the top 25 collaborators of Inga Rose. A scholar is included among the top collaborators of Inga Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inga Rose. Inga Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Gatalica, Zoran, Inga Rose, Monika Ulamec, et al.. (2023). The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status. SHILAP Revista de lepidopterología. 24(2). 256–261. 3 indexed citations
2.
Günther, Julia, et al.. (2022). Dietary Supplementation Before, During and After Pregnancy: Results of the Cluster-Randomized GeliS Study. Geburtshilfe und Frauenheilkunde. 82(7). 736–746. 1 indexed citations
3.
Vranić, Semir, et al.. (2017). Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. Annals of Diagnostic Pathology. 33. 62–68. 4 indexed citations
4.
Gatalica, Zoran, Ari M. Vanderwalde, Inga Rose, et al.. (2016). Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases.. Journal of Clinical Oncology. 34(15_suppl). 11548–11548. 8 indexed citations
5.
Masir, Noraidah, et al.. (2016). Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.. PubMed. 38(3). 229–233. 6 indexed citations
6.
Gatalica, Zoran, Carrie Snyder, Todd Maney, et al.. (2014). Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. Cancer Epidemiology Biomarkers & Prevention. 23(12). 2965–2970. 416 indexed citations breakdown →
7.
Gatalica, Zoran, Anatole Ghazalpour, Daniel A. Holterman, et al.. (2014). Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.. Journal of Clinical Oncology. 32(15_suppl). e22091–e22091. 6 indexed citations
8.
Kemkes, Ariane, et al.. (2012). Differences in biomarker expression in HNSCC according to p53 status.. Journal of Clinical Oncology. 30(15_suppl). 5523–5523. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026